Deutsch English Français

Contact

EP2760457

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2760457

EP2760457 - METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 26.08.2016 Database last updated on 12.10.2024
Most recent event Tooltip	26.08.2016	Application deemed to be withdrawn	published on 28.09.2016 [2016/39]
Applicant(s)	For all designated states Agency for Science, Technology and Research 1 Fusionopolis Way 20-10 Connexis Singapore 138632 / SG
	[2014/32]
Inventor(s)	01 / YU, Qiang 60 Biopolis Street, 02-01 Singapore 138672 / SG
	02 / LEE, Shuet, Theng 60 Biopolis Street, 02-01 Singapore 138672 / SG
	[2014/32]
Representative(s)	HGF Delta House 50 West Nile Street Glasgow G1 2NP / GB
	[N/P]
Former [2014/32]	HGF Limited Delta House 50 West Nile Street Glasgow G1 2NP / GB
Application number, filing date	12836890.9	28.09.2012
	WO2012SG00364
Priority number, date	SG20110007036	28.09.2011 Original published format: SG 201107036
	[2014/32]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013048345
	Date:	04.04.2013
	Language:	EN
	[2013/14]
	Type:	A1 Application with search report
	No.:	EP2760457
	Date:	06.08.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 04.04.2013 takes the place of the publication of the European patent application.
	[2014/32]
Search report(s)	International search report - published on:	AU	04.04.2013
	(Supplementary) European search report - dispatched on:	EP	08.06.2015
Classification	IPC:	A61K31/713, A61K31/4196, A61K39/395, A61K47/02, A61K31/517, A61P35/04, A61P43/00, C12N15/113	[2014/32]
	CPC:	C12N15/1135 (EP,US); A61K31/47 (EP,US); A61K31/4709 (EP,US); A61K31/517 (EP,US); A61K31/519 (EP,US); A61K31/5377 (EP,US); (+) A61K31/7088 (EP,US); A61K31/713 (EP,US); A61K45/06 (EP,US); A61P35/04 (EP); A61P43/00 (EP); C12N15/113 (EP,US); C12Q1/6881 (US); C12N2310/14 (EP,US); C12N2320/31 (EP,US); C12Q2600/106 (US) (-)
	C-Set:	A61K31/4709, A61K2300/00 (US,EP); A61K31/47, A61K2300/00 (EP,US); A61K31/517, A61K2300/00 (US,EP); A61K31/5377, A61K2300/00 (US,EP); (+) A61K31/713, A61K2300/00 (EP,US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/32]
Title	German:	VERFAHREN UND PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON KREBS	[2014/32]
	English:	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER	[2014/32]
	French:	PROCÉDÉS ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT DU CANCER	[2014/32]
Entry into regional phase	28.03.2014	National basic fee paid
	28.03.2014	Search fee paid
	28.03.2014	Designation fee(s) paid
	28.03.2014	Examination fee paid
Examination procedure	28.03.2014	Examination requested [2014/32]
	23.12.2015	Amendment by applicant (claims and/or description)
	06.04.2016	Application deemed to be withdrawn, date of legal effect [2016/39]
	12.05.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the invitation to file a copy of earlier search results or a statement of non-availability not received in time [2016/39]
Fees paid	Renewal fee
	24.07.2014	Renewal fee patent year 03
	28.09.2015	Renewal fee patent year 04
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XA]WO2004030615 (GENENTECH INC [US], et al) [X] 1-3,6,8 * claims 77,89-91,102; sequence 3416 * [A] 4,5,7,9-15;
		[XA]WO2008034133 (UNIV TEMPLE [US], et al) [X] 6 * paragraphs [0130] , [0131] , [0150] * [A] 1-5,7-15;
		[IA] - RAGUZ ET AL, "Suppressor of T-cell receptor signalling 1 and 2 differentially regulate endocytosis and signalling of receptor tyrosine kinases", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20071002), vol. 581, no. 24, doi:10.1016/J.FEBSLET.2007.08.077, ISSN 0014-5793, pages 4767 - 4772, XP022262529 [I] 1-4,6-8,10-14 * abstract * [A] 5,9,15 DOI: http://dx.doi.org/10.1016/j.febslet.2007.08.077
		[T] - S. T. LEE ET AL, "Protein tyrosine phosphatase UBASH3B is overexpressed in triple-negative breast cancer and promotes invasion and metastasis", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20130619), vol. 110, no. 27, doi:10.1073/pnas.1300873110, ISSN 0027-8424, pages 11121 - 11126, XP055190557 DOI: http://dx.doi.org/10.1073/pnas.1300873110
	International search	[X]WO0002589 (UNIV MONASH [AU], et al);
		[X]WO2005027830 (UNIV VIRGINIA COMMONWEALTH [US], et al);
		[X]US2006194883 (OZAKI IWATA [JP], et al);
		[X]WO2008043561 (MAX PLANCK GESELLSCHAFT [DE], et al);
		[X]US7517644 (SMITH LARRY J [US]);
		[X]WO2010017443 (DA ZEN GROUP LLC [US], et al);
		[X]US7820809 (KHVOROVA ANASTASIA [US], et al);
		[X]WO2011005793 (ALNYLAM PHARMACEUTICALS INC [US], et al);
		[XP]WO2012071492 (GEORGIA TECH RES INST [US], et al);
		[X] - SUREBAN, S. M. ET AL., "Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism", JOURNAL OF NANOBIOTECHNOLOGY, (20110919), vol. 9, no. 40, pages 1 - 13, XP021110668 DOI: http://dx.doi.org/10.1186/1477-3155-9-40
		[X] - XIA, H. ET AL., "miR-200a Regulates Epithelial-Mesenchymal to Stem-like Transition via ZEB2 and beta-Catenin Signaling", JOURNAL OF BIOLOGICAL CHEMISTRY, (2010), vol. 285, no. 47, pages 36995 - 37004, XP055147411 DOI: http://dx.doi.org/10.1074/jbc.M110.133744
		[X] - ITO, H. ET AL., "Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2", CANCER RESEARCH, (2004), vol. 64, pages 7439 - 7446, XP055147414 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-04-1177
		[X] - ZHANG, Y. ET AL., "miR-125b Is Methylated and Functions as a Tumor Suppressor by Regulating the ETS1 Proto-oncogene in Human Invasive Breast Cancer", CANCER RESEARCH, (201103), vol. 71, pages 3552 - 3562, XP055147417 DOI: http://dx.doi.org/10.1158/0008-5472.CAN-10-2435
		[X] - KITA, D. ET AL., "Expression of Dominant-negative Form of Ets-1 Suppresses Fibronectin-stimulated Cell Adhesion and Migration Through Down-Regulation of Integrin alpha5 Expression in U251 Glioma Cell Line", CANCER RESEARCH, (2001), vol. 61, pages 7985 - 7991, XP055147421
		[X] - ZHAO, J. ET AL., "Thirty-Kilodalton Tat-Interacting Protein Suppresses Tumor Metastasis by Inhibition of Osteopontin Transcription in Human Hepatocellular Carcinoma", HEPATOLOGY, (2008), vol. 48, pages 265 - 275, XP055147422 DOI: http://dx.doi.org/10.1002/hep.22280

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p